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Kahramanmaras Sutcu Imam University, TurkeyObjectives. To compare the efficacy of a single prophylactic dose of intra-peritoneal vancomycin and teicoplanin with anti-
biotic treated Dacron grafts (vancomycin, teicoplanin, 10 or 40% fusidic acid-soaked grafts) in preventing vascular graft
infections in a rat model.
Design. Prospective, randomized, controlled animal study.
Materials and methods. The graft infections were established in the subcutaneous tissues of 80 female Sprague–Dawley
rats by the implantation of Dacron prostheses followed by the topical inoculation with methicillin-resistant Staphylococcus
aureus. The study groups were as follows: (1) uncontaminated control group, (2) untreated contaminated group, (3)
contaminated group with intra-peritoneal vancomycin, (4) contaminated group with intra-peritoneal teicoplanin, (5)
contaminated group received vancomycin-soaked Dacron graft, (6) contaminated group received teicoplanin-soaked Dacron
graft, (7) contaminated group received 40% fusidic acid-soaked Dacron graft, and (8) contaminated group received 10%
fusidic acid-soaked Dacron graft prophylaxis. The grafts were removed after 7 days and evaluated by a quantitative culture
analysis.
Results. No infection was detected in controls. The untreated contaminated group had a high bacteria count (6.0!
104 CFU/cm2 Dacron graft). Groups that received intra-peritoneal vancomycin or teicoplanin had less bacterial growth
(4.8!103 and 3.9!103 CFU/cm2 Dacron graft, respectively). Similarly, the group that received 10% fusidic acid-soaked
graft showed less bacterial growth (3.6!103 CFU/cm2 Dacron graft). The groups with vancomycin-, teicoplanin- and 40%
fusidic acid-soaked grafts showed no evidence of infection. Statistical analyses demonstrated that intra-peritoneal
prophylactic antibiotic treatment was less effective in inhibiting bacterial growth than high concentration antimicrobial-
soaking of grafts.
Conclusion. The use of vancomycin-, teicoplanin- and 40% fusidic acid-soaked grafts was effective in preventing primary
prosthetic vascular graft infection.Keywords: Vascular graft infection; Antibiotic prophylaxis; Rat model; Vancomycin; Teicoplanin; fusidic acid.Introduction
The infection of vascular prosthetic grafts is a relatively
uncommon phenomenon, with a reported incidence of
between 0.5 and 8%.1–9 The infection rate depends on
the site of the reconstruction and the graft material
used.4 The incidence probably has been reduced by
perioperative systemic antibiotic prophylaxis, shorter
duration of procedures and minimization of blood loss,
but the overall prevalence is increasing in parallel with
the expansion in vascular reconstructive surgery.4,10ing author. Alptekin Yasim, MD, Department of
lar Surgery, Faculty of Medicine, Kahramanmaras
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0274 + 06 $35.00/0 q 2006 Elsevier Ltd. All rights reserAlthough new antimicrobial compounds are being
used for prevention, vascular graft infection is still one
of the most feared complications. It frequently results in
prolonged hospitalization, organ failure, amputation
and death. Mortality and amputation rates have been
reported to be as high as 12–75 and 19–79%,
respectively.1,4,7,11
The mechanism(s) of graft infection may be peri-
operative contamination, postoperative wound infec-
tion or systemic bacteraemia. The usual time for the
entry of microorganisms is at operation; although they
may be blood-born or lymphatic in origin, the
probability of their presence in the arterial wall cannot
be excluded.1–5,8,9 The most frequent source of
infection is staphylococci deriving from the patient’sEur J Vasc Endovasc Surg 31, 274–279 (2006)
doi:10.1016/j.ejvs.2005.09.018, available online at http://www.sciencedirect.com onved.
Vascular Graft Infection 275skin. Other potential sites include the urinary tract,
intravascular loci, lung and pleural space, peritoneal
cavity and finally surgical sites including prosthetic
devices.12 Prevention of these infections would have
an important impact on patient mortality and the cost
effectiveness of hospital care.13 The mainstays of
prophylaxis are asepsis and peri-operative adminis-
tration of systemic antibiotics.3,13–15 The choice of
antibiotics and the length of the treatment are
controversial although the first and second generation
cephalosporins have been the most commonly used
drugs.2,12–14,16 However, after initial success, resist-
ance to these drugs began to emerge. In particular, the
widespread use of several antimicrobial agents, either
in therapeutic or prophylactic regimens, resulted in a
dramatic increase in the prevalence of multi-drug-
resistant organisms, such as methicillin-resistant
staphylococci.
In earlier reports, Staphylococcus epidermidis was
found to be the most frequent cause of vascular graft
infections, however, methicillin-resistant Staphylococ-
cus aureus (MRSA) recently was reported to be the
most common organism isolated in vascular graft
infections.2,3,5,10,11,14–18 MRSA graft infections were not
associated with an increased risk of death but were
associated with a significant increase in the risk of
amputation and prolonged duration of hospitality.3,17
Despite the use of systemic antibiotic prophylaxis,
vascular graft infections still occur. For this reason,
antibiotic- and antimicrobial-impregnated grafts have
recently been used in the several experimental and
clinical studies for the prevention of vascular graft
infections.2,6,7,12–15,19–21 These grafts have been shown
to be highly resistant to bacterial contamination and
proposed as adjunctive prophylaxis.2,12,14,15,20 In
clinical studies, rifampin-impregnated Dacron grafts
have been used for prevention of vascular graft
infection. Other antibiotic-bonded grafts have only
been used in experimental studies, not in clinical
studies.
In clinical settings, glycopeptide antibiotics are in
widespread use for the treatment of vascular graft
infection, although they are not used for routine
prophylaxis of vascular graft infection. If there is a
risk of MRSA infection, glycopeptides may be used to
prevent vascular graft infection. To date, there has
been no study evaluating the use and comparison of
intra-peritoneal and topical glycopeptides for the
prevention of vascular graft infection. Therefore, we
investigated the efficacy of topical and intra-peritoneal
vancomycin and teicoplanin, as well as topical fusidic
acid to prevent MRSA vascular graft infection in a rat
model.Material and MethodsOrganisms
The strain of methicillin-resistant S. aureus used in this
study was isolated from a clinical specimen submitted
for routine bacteriological investigation to the Depart-
ment of Microbiology, Faculty of Medicine, Kahra-
manmaras Sutcu Imam University, Turkey.
Commercially available S. aureus ATCC 25923 was
used as a control in susceptibility testing.Drugs
Vancomycin (Vankomisin HCI), teicoplanin (Targocid)
and fusidic acid (Fucidin krem 2%) were obtained
from Abbott Laboratories (Istanbul, Turkey), Aventis
Pharma (Istanbul, Turkey) and Abdi Ibrahim Drug
Company (Istanbul, Turkey), respectively. Fusidic acid
prepared as 10 and 40% was dissolved in 100 cm3
ClinOleic 20% (Eczacıbas¸ı-Baxter, Istanbul, Turkey).Susceptibility testing
The antimicrobial susceptibilities of two MRSA strains
were determined by using the micro-broth dilution
method, according to the procedures outlined by the
National Committee for Clinical Laboratory Stan-
dards. The minimum inhibition concentration was
taken to be the lowest antibiotic concentration at
which observable growth was inhibited. Experiments
were performed in triplicate.Rat model
The study was approved by the Ethics Committee of
Faculty of Medicine, Kahramanmaras Sutcu Imam
University, Turkey. Adult female Sprague–Dawley
rats (weight range, 200–250 g) were studied. All rats
had free access to standard rat chow and tap water.
The study included a control group with no graft
contamination and no antibiotic prophylaxis
(group 1), one contaminated group that did not
receive any antibiotic prophylaxis (group 2), one
contaminated group that received peri-operative
10 mg/kg intra-peritoneal vancomycin (group 3),
one contaminated group that received peri-operative
10 mg/kg intra-peritoneal teicoplanin (group 4), four
contaminated groups that separately received vanco-
mycin-, teicoplanin-, fusidic acid 10%- and fusidic
acid 40%-soaked grafts (group 5, 6, 7 and 8,
respectively). Each group consisted of 10 animals.Eur J Vasc Endovasc Surg Vol 31, 3 2006
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mine (10 mg/kg) and xylazine (3 mg/kg), the backs
shaved and the skin cleaned with 10% povidone–
iodine solution. One subcutaneous pocket was made
on the right side of the median line by a 1.5 cm
incision. Aseptically, 1 cm2 sterile gelatin-sealed
Dacron grafts (Gelseal; Sulzer Vascutek Ltd, UK)
were implanted into the pockets. Prior to implan-
tation, the Dacron graft segments were impregnated
with 50 mg/L vancomycin (group 5), 50 mg/L
teicoplanin (group 6), 10% fusidic acid (group 7)
and 40% fusidic acid (group 8). Antibiotic soaking
was done immediately before implantation by
placing the grafts for 20 min in a sterile solution
of the relevant agent. Biochemical assessment of
antibiotic binding to soaked graft was not perfor-
med.The pockets were closed by 5/0 polypropylene
sutures (Dogsan, Turkey), and a sterile saline
solution (1 mL) containing the MRSA strain at a
concentration of 2!107 CFU/mL was inoculated
onto the graft surface using a tuberculin syringe to
create a subcutaneous fluid-filled pocket. The
animals were returned to individual cages and
thoroughly examined daily. All grafts were
explanted after 7 days following implantation. At
this stage, to investigate the existence of an infection
blood samples were collected for the culture
analysis.Assessment of the infection
The explanted grafts were placed in sterile tubes,
washed in sterile saline solution, placed in tubes
containing 10 mL of phosphate-buffered saline
solution and sonicated for 5 min to remove the
adherent bacteria from the grafts. Quantification of
viable bacteria was performed by preparing serial 10-
fold dilutions (0.1 ml) of the bacterial suspensions in
10 mM buffer to minimize the carryover effect and by
culturing each dilution on blood agar plates. All plates
were incubated at 37 8C for 48 h and evaluated for the
presence of MRSA. The organisms were quantified by
counting the number of colony forming units (CFU)
per plate. The limit of detection for this method was
approximately 50 CFU/cm2 of graft tissue.Statistical analysis
Quantitative culture results for all groups are pre-
sented as meanGstandard deviation and statistical
comparisons between groups were performed using
analysis of variance (ANOVA) on the log-transformed
data with differences between groups assessed withEur J Vasc Endovasc Surg Vol 31, 3 2006Turkey significant difference test. Statistical signifi-
cance was defined as a p value of !0.05.Results
None of the animals included in the uncontaminated
control group (group 1) had either anatomic or
microbiological evidence of graft infection. In contrast,
all rats in the contaminated group that did not
receive any antibiotic prophylaxis (group 2) demon-
strated graft infections, evidenced by the quantitative
culture results showing 6!104G2!104 CFU/cm2
graft within local signs of perigraft inflammation,
p!0.001 versus group 1. The intra-peritoneal vanco-
mycin treated group (group 3) had less bacterial
growth, 4.8!103G1.8!103 CFU/cm2 graft, but with-
out local signs of perigraft inflammation, p!0.002 and
p!0.001 versus groups 1 and 2 respectively. Similarly,
the intra-peritoneal teicoplanin treated group (group
4) had less bacterial growth, 3.9!103G2.6!
102 CFU/cm2 graft without local signs of perigraft
inflammation, p!0.001 versus groups 1 and 2. The
groups with vancomycin- and teicoplanin-soaked
Dacron graft (group 5 and 6) showed no evidence of
staphylococcal infection with negative quantitative
cultures, both p!0.003 versus unsoaked graft and same
antibiotic given intra-peritoneally. For group 7, where
10% fusidic acid soaked -Dacron graft was used, there
was low bacterial growth (3.6!103G2.2!103), whilst
in group 8, with 40% fusidic acid soaked grafts, there
was no evidence of graft infection (p!0.001). While
the bacterial growth of group 7 was significantly lower
than those of group 1, 5 and 6 (p!0.001), it was similar
with those of group 3 and 4. The results are
summarized in Table 1.
Blood cultures were negative in all rats. Finally,
none of the animals included in any group died or had
clinical evidence of drug-related adverse effects, such
as anorexia, vomiting, diarrhea, or other symptoms.Discussion
The widespread use of several antimicrobial agents
in both therapeutic and prophylactic regimens has
resulted in a significant increase in the prevalence of
multi-drug-resistant organisms, such as MRSA. The
short doubling times and genetic plasticity of
bacteria permit these organism to rapidly prove
specific mutations for their ability to enhance growth
in inhospitable environments. Mutations conferring
resistance help bacteria to survive attach from
antibiotics used clinically.14,16 Graft infection with
Table 1. Quantitative microbiological results of in vivo experiments
Group Method of prophylaxis Quantitative graft culture (CFU/cm2)
1 – 0
2 – 6.0!104G2.0!104 *
3 Intra-peritoneal vancomycin (10 mg/kg) 4.8!103G1.8!103 *,†
4 Intra-peritoneal teicoplanin (10 mg/kg) 3.9!103G2.6!102 *,†
5 Vancomycin-soaked graft (50 mg/L) 0†,‡,§
6 Teicoplanin-soaked graft (50 mg/L) 0†,‡,§
7 Fusidic acid-soaked graft (10%) 3.6!103G2.2!103 *,†,¶,s
8 Fusidic acid-soaked graft (40%) 0†,‡,§,**
Each group consisted of 10 animals and statistical significance was evaluated by the use analysis of variance (ANOVA) on the log-
transformed data by the Turkey significant difference test.
* Statistically significant versus group 1.
† Statistically significant versus group 2.
‡ Statistically significant versus group 3.
§ Statistically significant versus group 4.
¶ Statistically significant versus group 5.
s Statistically significant versus group 6.
** Statistically significant versus group 7.
Vascular Graft Infection 277MRSA has emerged as a significant problem among
hospitalized patients. The emergence of the resistant
organisms has stimulated research for new antimi-
crobial drugs and biomaterials. The development of
vascular prostheses resistant to infection has con-
siderable appeal, but as yet, none are commercially
available. For vascular grafts, antimicrobials
bounded at high concentrations to prosthetic grafts
have been proposed as adjunctive prophylaxis, with
encouraging results.2,12,14–16,20,21 One focus has been
the development of a bacterial resistant vascular
prosthesis through binding of an antibiotic to Dacron
grafts, with impregnated collagen or gelatin matrix
as the release system. Such antibiotic-impregnated
grafts have been shown to be highly resistant to
bacterial contamination in animal models.
Rifampin-soaked Dacron grafts have been used
successfully. Nevertheless, the development of the
rifampicin-resistance would be a major drawback to
the wide-spread use of such a graft and emphasizes
the need for further prophylactic approaches.16
We compared the efficacy of systemic vancomycin
and teicoplanin prophylaxis with antibiotic (vanco-
mycin, teicoplanin or fusidic acid) soaked Dacron
grafts in a MRSA vascular graft infection model.
Resistance to these antibiotics is uncommon and they
show activity against clinically important staphylo-
cocci. These features were the main reasons of
preferring these agents in the present study. The
glycopeptides, vancomycin and teicoplanin, are
bactericidal agents with the ability to inhibit bacterial
cell wall synthesis. Teicoplanin is preferable to
vancomycin, since it has fewer side-effects, e.g.
nephrotoxicity and ototoxicity, and therapeutic drug
monitoring is usually unnecessary.3,22 Fusidic acid is
a topical antibiotic that has an effective narrow-spectrum antibiotic for the treatment of gram-
positive bacteria including MRSA and inhibits
bacterial protein synthesis. It is used for the
treatment of superficial skin infection due to
S. aureus. Fusidic acid is active against most MRSA
strains because of its wide tissue distribution, high
tolerability, lack of cross-resistance with b lactam
antibiotics and good antimicrobial activity against
S. aureus (including MRSA).18,22 We chose Dacron in
this study as many investigators due to its less
resistance to bacterial adherence than polytetrafluor-
oethylene.15 However, we did not assess anti-biotic
binding to the Dacron grafts, which is a limitation of
the present study.
Our study examining the primary prevention of
vascular graft infection with vancomycin- and
teicoplanin-soaked grafts has shown these antibiotics
to be effective. For primary prevention of vascular
graft infection, single doses of intra-peritoneal
vancomycin and teicoplanin appear less effective
than vancomycin- and teicoplanin-soaked grafts.
Perhaps a single parenteral dose of antibiotic was
insufficient for prevention of prosthetic vascular graft
infection. No bacterial growth was detected on the
vancomycin- and teicoplanin-soaked Dacron grafts.
Although Giacometti et al. found that graft infection
with multiple-drug-resistant S. epidermidis in a rat
model was higher in vancomycin- and teicoplanin-
coated Dacron grafts than in those coated with
polycationic peptides (ranalexin and bufforin), the
microorganism they used already had intermediate
resistance to glycopeptide antibiotics.15 They also
investigated the efficacies of polycationic peptides,
ranalexin and bufforin, in the rat model, and
compared these peptides-soaked grafts with rifam-
pin-soaked graft and intra-peritoneal cefazolinEur J Vasc Endovasc Surg Vol 31, 3 2006
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polycationic peptides against the methicillin-suscep-
tible and methicillin-resistant S. epidermidis strains
were not significantly different from that
of rifampin.14 Vicaretti and colleagues established a
S. epidermidis vascular graft infection model in sheep
and suggested that an increased concentration of
rifampin bound to Dacron grafts significantly
reduced the incidence of prosthetic vascular graft
infection following a challenge of drug-resistant
staphylococci.5 Numerous other models, with differ-
ent microorganisms, antibiotics and regimens have
been reported. However, there is little evidence for
the use of fusidic acid.
We investigated the in vivo efficacy of two different
concentrations of fusidic acid spontaneously bound to
gelatin-sealed Dacron graft, in the prevention of S.
aureus infection. Our experiments demonstrated that
40% fusidic acid was considerably more effective than
10% fusidic acid. Forty percent fusidic acid completely
inhibited bacterial growth of MRSA strains even
though multi-resistant organisms were topically inocu-
lated on the Dacron prosthesis. There was no evidence
of fusidic acid toxicity in our study. Ghiselli et al.
investigated another topical antibiotic mupirocin and
reported mupirocin-soaked graft to be more effective
than rifampin-soaked graft against MRSA.16 Giaco-
metti and colleagues investigated mupirocin-bound
Dacron grafts for preventing infection of the graft in a
rat model and showed that mupirocin was more
effective than vancomycin against S. aureus.20 In view
of these results, the optimal management for preven-
tion of vascular graft infection remains controversial.
However, the use of antibiotic-impregnated prosthetic
grafts may become an important future consideration
for chemoprophylaxis in vascular surgery.
In conclusion, vancomycin, teicoplanin and 40%
fusidic acid treatment of Dacron grafts is effective in
preventing primary graft infection in an experimental
model. Our experience with antibiotic-soaked grafts in
the management of vascular graft infections suggest
that this technique seems to be a useful option for
treating one of the most dreaded vascular compli-
cations. Indeed, new antimicrobial-coated grafts are
future options for the development of protocols
designed to prevent graft infection.References
1 Huh J, Chen JC, Furman GM, Malki C, King B, Kafie F et al.
Local treatment of prosthetic vascular graft infection with
multivesicular liposome-encapsulated amikacin. J Surg Res
1998;74:54–58.Eur J Vasc Endovasc Surg Vol 31, 3 20062 Lehnhardt FJ, Torsello G, Claeys LGY, Pfeiffer M, Wachol-
Drewek Z, Grundmann RT et al. Systemic and local antibiotic
prophylaxis in the prevention of prosthetic vascular graft
infection: an experimental study. Eur J Vasc Endovasc Surg 2002;
23:127–133.
3 Earnshaw JJ. Methicillin-resistant Staphylococcus aureus: vascular
surgeons should fight back. Eur J Vasc Endovasc Surg 2002;24:283–
286.
4 Jones L, Braithwaite BD, Davies B, Heather BP, Earnshaw JJ.
Mechanism of late prosthetic vascular graft infection. Cardiovasc
Surg 1997;5:486–489.
5 Vicaretti M, Hawthorne WJ, Ao PY, Fletcher JP. An increased
concentration of rifampicin bonded to gelatin-sealed Dacron
reduced the incidence of subsequent graft infections following a
staphylococcal challenge. Cardiovasc Surg 1998;6:268–273.
6 Hernandez-Richter T, Schardey HM, Lo¨hlein F, Heiss MM,
Redondo-Mu¨ller M, Hammer C et al. The prevention and
treatment of vascular graft infection with a triclosan (irgasan)-
bonded Dacron graft: an experimental study in the pig. Eur J Vasc
Endovasc Surg 2000;20:413–418.
7 Hernandez-Richter T, Schardey HM, Wittman F, Mayr S,
Schmitt-Sody M, Blasenbreu S et al. Rifampin and triclosan but
not silver is effective in preventing bacterial infection of vascular
Dacron graft material. Eur J Vasc Endovasc Surg 2003;26:550–557.
8 Fujita M, Kinoshita M, Ishihara M, Kanatani Y,
Morimoto Y, Simizu M et al. Inhibition of vascular prosthetic
graft infection using a photocrosslinkable chitosan hydrogel.
J Surg Res 2004;121:135–140.
9 Sago T, Mori Y, Takagi H, Iwata H, Murase K, Kawamura Yet al.
Local treatment of Dacron patch graft contaminated with Staphylo-
coccus aureus with antibiotic-releasing porous apatite ceramic: an
experimental study in the rabbit. J Vasc Surg 2003;37:169–174.
10 Gabriel M, Pukacki F, Dzieciuchowicz L, Oszkinis G,
Checinski P. Cryopreserved arterial allografts in the treatment
of prosthetic graft infections. Eur J Vasc Endovasc Surg 2004;27:
590–596.
11 Henke PK, Bergamini TM, Rose SM, Richardson JD.
Current options in prosthetic vascular graft infection. Am Surg
1998;64:39–46.
12 Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F,
Orlando F, Del Prete MS et al. Quinupristin/dalfopristin
bonding in combination with intra-peritoneal antibiotics prevent
infection of knitted polyester graft material in a subcutaneous rat
pouch model infected with resistant Stapylococcus epidermidis. Eur
J Vasc Endovasc Surg 2002;24:230–234.
13 Ghiselli R, Giacometti A, Goffi L, Cirioni O, B¨occoli G,
Mocchegiani F et al. Efficacy of rifampin–levofloxacin as a
prophylactic agent in preventing Staphylococcus epidermidis graft
infection. Eur J Vasc Endovasc Surg 2000;20:508–511.
14 Giacometti A, Cirioni O, Ghiselli R, Goffi L, Mocchegiani F,
Riva A et al. Policationic peptides as prophylactic agents against
methicillin-susceptible or methicillin-resistant Staphylococcus
epidermidis vascular graft infection. Antimicrob Agents Chemother
2000;44:3306–3309.
15 Giacometti A, Cirioni O, Ghiselli R, Goffi L, Mocchegiani F,
Riva A et al. Efficacy of polycationic peptides in preventing
vascular graft infection due to Staphylococcus epidermidis.
J Antimicrob Chemother 2000;46:751–756.
16 Ghiselli R, Giacometti A, Goffi L, Cirioni O, Mocchegiani F,
Orlando F et al. Prophylaxis against Staphylococcus aureus
vascular graft infection with mupirocin-soaked, collagen-sealed
Dacron. J Surg Res 2001;99:316–320.
17 Naylor AR, Hayes PD, Darke S. A prospective audit of complex
wound and graft infections in Great Britain and Ireland: the
emergence of MRSA. Eur J Vasc Endovasc Surg 2001;21:289–294.
18 Nasim A, Thompson MM, Naylor AR, Bell PRF, London NJM.
The impact of MRSA on vascular surgery. Eur J Vasc Endovasc
Surg 2001;22:211–214.
19 Ghiselli R, Giacometti A, Cirioni O, Dell’Acqua G,
Mocchegiani F, Orlando F et al. RNAIII-inhibiting peptide
and/or nisin inhibit experimental vascular graft infection with
Vascular Graft Infection 279methicillin-susceptible and methicillin-resistant Staphylococcus
epidermidis. Eur J Vasc Endovasc Surg 2004;27:603–607.
20 Giacometti A, Cirioni O, Ghiselli R, Goffi L, Viticchi C,
Mocchegiani F et al. Mupirocin prophylaxis against methicillin-
susceptible, methicillin-resistant, or vancomycin-intermediate
Staphylococcus epidermidis vascular graft infection. Antimicrob
Agents Chemother 2000;44:2842–2844.
21 Cirioni O, Giacometti A, Ghiselli R, Dell’Acqua G, Gov Y,
Kamysz W et al. Prophylactic efficacy of topical temporin A and
RNAIII-inhibiting peptide in a subcutaneous rat pouch model ofgraft infection attributable to staphylococci with intermediate
resistance to glycopeptides. Circulation 2003;108:767–771.
22 Ersoz G, Oztuna V, Coskun B, Eskandari MM, Bayarslan C,
Kaya A. Addition of fusidic acid impregnated bone cement to
systemic teicoplanin therapy in the treatment of rat osteomyelitis.
J Chemother 2004;16:51–55.
Accepted 23 September 2005
Available online 15 December 2005Eur J Vasc Endovasc Surg Vol 31, 3 2006
